A detailed history of Lazard Asset Management LLC transactions in Prothena Corp Public LTD CO stock. As of the latest transaction made, Lazard Asset Management LLC holds 42,173 shares of PRTA stock, worth $669,707. This represents 0.0% of its overall portfolio holdings.

Number of Shares
42,173
Holding current value
$669,707
% of portfolio
0.0%

Shares

6 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$16.73 - $24.79 $705,554 - $1.05 Million
42,173 New
42,173 $705,000
Q4 2023

Feb 14, 2024

BUY
$32.31 - $52.32 $137,511 - $222,673
4,256 New
4,256 $154,000
Q1 2023

May 15, 2023

BUY
$46.97 - $58.27 $57,679 - $71,555
1,228 New
1,228 $59,000
Q1 2022

May 13, 2022

BUY
$30.27 - $49.22 $19,887 - $32,337
657 Added 61.06%
1,733 $63,000
Q4 2021

Feb 09, 2022

BUY
$42.11 - $73.26 $6,653 - $11,575
158 Added 17.21%
1,076 $53,000
Q3 2021

Nov 15, 2021

BUY
$48.2 - $78.89 $44,247 - $72,421
918 New
918 $65,000

Others Institutions Holding PRTA

About PROTHENA CORP PUBLIC LTD CO


  • Ticker PRTA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 46,922,800
  • Market Cap $745M
  • Description
  • Prothena Corporation plc, a late-stage clinical company, focuses on discovery and development of novel therapies for life-threatening diseases in the United States. The company is involved in developing Birtamimab, an investigational humanized antibody that is in Phase III clinical trial for the treatment of AL amyloidosis; Prasinezumab, a human...
More about PRTA
Track This Portfolio

Track Lazard Asset Management LLC Portfolio

Follow Lazard Asset Management LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Lazard Asset Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Lazard Asset Management LLC with notifications on news.